A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device (VELOCITY)
A Feasibility Registry on Use of Actigraphy Monitoring in Degenerative Mitral Regurgitation (DMR) Subjects Receiving the MitraClip® Device
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Banner University Medical Center
-
-
California
-
Los Angeles, California, Forenede Stater, 90048
- Cedars-Sinai Medical Center
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- University Of Colorado Hospital
-
-
Florida
-
Miami, Florida, Forenede Stater, 33176
- Baptist Hospital of Miami
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Mayo Foundation for Medical Education and Research
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- The Cleveland Clinic Foundation
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23226
- Bon Secours St Mary's Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Subject must consent to receiving the MitraClip device
- Subject must consent, be able, and commit to wearing the Actiwatch continuously for approximately 7 months
- Subject must consent to use of their data from this registry for purposes of exploratory research and publication and presentation
Exclusion Criteria:
- Subject is not a member of vulnerable population
- Subject must not have any disabilities that preclude reliable data collection from the Actiwatch, e.g., epilepsy with uncontrolled recurring episodes, serious stage degenerative/disabling disease (e.g. Parkinson's disease), inability to walk or will require walking aids, etc.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Commercial MitraClip® patients
Patients with Degenerative Mitral Regurgitation receiving MitraClip® Device
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Observational change in daily reported activity levels (counts/min) as assessed by actigraphy, from baseline to 30 days post MitraClip implantation
Tidsramme: At 30 days
|
Phillips Actiwatch Spectrum PRO is the device being used to capture the primary outcome measure
|
At 30 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: Pre-procedure (on day 0)
|
Pre-procedure (on day 0)
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: At 30 days
|
At 30 days
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: At 2 months
|
At 2 months
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: At 3 months
|
At 3 months
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: At 4 months
|
At 4 months
|
|
Levels of daily and weekly activity as assessed by actigraphy
Tidsramme: At 5 months
|
At 5 months
|
|
Patterns of daily Sleep/Wake by actigraphy
Tidsramme: At 6 months
|
At 6 months
|
|
NYHA Functional Class
Tidsramme: At Baseline
|
At Baseline
|
|
NYHA Functional Class
Tidsramme: At 30 days
|
At 30 days
|
|
Mitral Regurgitation severity
Tidsramme: At Baseline
|
At Baseline
|
|
Mitral Regurgitation severity
Tidsramme: Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
|
Mitral Regurgitation severity
Tidsramme: At 30 days
|
At 30 days
|
|
Echocardiographic assessment
Tidsramme: At Baseline
|
At Baseline
|
|
Echocardiographic assessment
Tidsramme: Post-procedure (≤ 7 days)
|
Post-procedure (≤ 7 days)
|
|
Echocardiographic assessment
Tidsramme: At 30 days
|
At 30 days
|
|
Distance walked 6 minute walk test (6MWT)
Tidsramme: At Baseline
|
At Baseline
|
|
Distance walked 6 minute walk test (6MWT)
Tidsramme: At 30 days
|
At 30 days
|
|
Health-related quality of life (QoL)
Tidsramme: At Baseline
|
At Baseline
|
|
Health-related quality of life (QoL)
Tidsramme: At 30 days
|
At 30 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 16-6001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .